Cardiomyopathies in Noonan syndrome and the other RASopathies
- 31 January 2015
- journal article
- review article
- Published by Elsevier BV in Progress in Pediatric Cardiology
- Vol. 39 (1), 13-19
- https://doi.org/10.1016/j.ppedcard.2015.01.002
Abstract
No abstract availableFunding Information
- National Institutes of Health (R01 HL071207, GGP13107)
- Telethon-Italy
This publication has 40 references indexed in Scilit:
- MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutationJCI Insight, 2011
- Survival Implications: Hypertrophic Cardiomyopathy in Noonan SyndromeCongenital Heart Disease, 2011
- Reduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1FEBS Letters, 2006
- Contemporary Definitions and Classification of the CardiomyopathiesCirculation, 2006
- The natural history of Noonan syndrome: a long-term follow-up studyArchives of Disease in Childhood, 2006
- PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, EffectsPublished by Elsevier BV ,2006
- Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activationHuman Mutation, 2004
- Grouping of Multiple-Lentigines/LEOPARD and Noonan Syndromes on the PTPN11 GeneAmerican Journal of Human Genetics, 2002
- Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canalThe Journal of Pediatrics, 1999
- An infant with Costelio syndrome complicated with fatal hypertrophic obstructive cardiomyopathyPediatrics International, 1998